Samstag, Juli 30, 2022
StartBiotechnologyNew patent for Novartis drug RYDAPT – DrugPatentWatch

New patent for Novartis drug RYDAPT – DrugPatentWatch


Copyright © DrugPatentWatch. Initially printed at New patent for Novartis drug RYDAPT

Annual Drug Patent Expirations for RYDAPT
Annual Drug Patent Expirations for RYDAPT

Rydapt is a drug marketed by Novartis and is included in a single NDA. It’s out there from one provider. There are three patents defending this drug.

Drug patent litigation for RYDAPT.

This drug has fifty-five patent relations in twenty-seven international locations.

The generic ingredient in RYDAPT is midostaurin. One provider is listed for this compound. Extra particulars can be found on the midostaurin profile web page.

For extra data on how DrugPatentWatch may also help together with your pharmaceutical enterprise intelligence wants, contact admin@DrugPatentWatch.com or go to www.DrugPatentWatch.com

Make Higher Choices with DrugPatentWatch

» Begin Your Free Trial Right this moment «

Copyright © DrugPatentWatch. Initially printed at New patent for Novartis drug RYDAPT

RELATED ARTICLES

Most Popular

Recent Comments